© 1994 by Oxford University Press
Journal of the National Cancer Institute, Vol. 86, No. 3, 228-230,
February 2, 1994
© 1994 Oxford University Press
Sensitivity of Multiple Myeloma to Imexon in the Human Tumor Cloning Assay
Section of Hematology and Oncology, Department of Medicine and the Arizona Cancer Center, University of Arizona College of Medicine, Tucson
*Correspondence to: Sydney E. Salmon M.D., Director, Arizona Cancer Center, University of Arizona College of Medicine, 1501 N. Campbell Ave., Tucson, AZ 85724.
BACKGROUND: The best treatment for patients with "hormone-refractory" metastatic prostate cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed.
PURPOSE: We investigated a combination of flutamide withdrawal and aminoglutethimide in suraminand hydrocortisone-pretreated patients with "hormone-refractory" prostate cancer.
METHODS: Twentynine patients with metastatic prostate cancer were treated with simultaneous flutamide withdrawal and aminoglutethimide (250 mg given orally four times daily). All patients were taking flutamide at the time of entry, and previous treatments with medical or surgical castration, flutamide, suramin, and hydrocortisone had failed in all of these patients. Because of suramin-induced adrenal insufficiency, all patients had previously received, and continued to receive, physiological doses of hydrocortisone. Treatment of all nonsurgically castrated patients had previously failed; however, these patients continued to receive depot leuprolide.
RESULTS: In 14 (48%) of 29 patients, the prostate-specific antigen (PSA) decreased by more than 80% for 4 or more weeks. Improvements in anemia, thrombocytopenia, softtissue masses, bone scans, and symptoms were also noted. Factors associated with response included prolonged flutamide pretreatment, a markedly elevated pretreatment PSA, and the absence of soft-tissue disease.
CONCLUSIONS: Flutamide withdrawal, when combined with the simultaneous administration of aminoglutethimide, is a therapeutically active approach in patients with "hormonerefractory" prostate cancer.
IMPLICATIONS: On the basis of these and additional data, we hypothesize that prolonged exposure to flutamide results in the selective proliferation of cancer cells containing a mutant androgen receptor that aberrantly recognizes flutamide metabolites and nonandrogenic steroids as androgenic stimuli. [J Natl Cancer Inst 86:222–227, 1994]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. F. Baker, T. Landowski, R. Dorr, W. R. Tate, J. M.C. Gard, B. E. Tavenner, T. Dragovich, A. Coon, and G. Powis The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response Clin. Cancer Res., June 1, 2007; 13(11): 3388 - 3394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dragovich, M. Gordon, D. Mendelson, L. Wong, M. Modiano, H.-H. S. Chow, B. Samulitis, S. O'Day, K. Grenier, E. Hersh, et al. Phase I Trial of Imexon in Patients With Advanced Malignancy J. Clin. Oncol., May 1, 2007; 25(13): 1779 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Evens, S. Prachand, B. Shi, M. Paniaqua, L. I. Gordon, and R. B. Gartenhaus Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent Clin. Cancer Res., February 15, 2004; 10(4): 1481 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dvorakova, C. M. Payne, M. E. Tome, M. M. Briehl, M. A. Vasquez, C. N. Waltmire, A. Coon, and R. T. Dorr Molecular and Cellular Characterization of Imexon-resistant RPMI8226/I Myeloma Cells Mol. Cancer Ther., January 1, 2002; 1(3): 185 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dvorakova, C. N. Waltmire, C. M. Payne, M. E. Tome, M. M. Briehl, and R. T. Dorr Induction of mitochondrial changes in myeloma cells by imexon Blood, June 1, 2001; 97(11): 3544 - 3551. [Abstract] [Full Text] [PDF]
|
|